Gene, Cell and Tissue

Published by: Kowsar

Evaluation of 40-bp Insertion/Deletion Polymorphism of MDM2 and the Risk of Childhood Acute Lymphoblastic Leukemia

Mohammad Hashemi 1 , 2 , * , Majid Naderi 3 , 4 , Ebrahim Eskandari Nasab 3 , Seyed Shahaboddin Hasani 2 , Simin Sadeghi Bojd 4 and Mohsen Taheri 3
Authors Information
1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Genetics of Non Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
4 Department of Pediatrics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Gene, Cell and Tissue: January 01, 2015, 2 (1); e26974
  • Published Online: January 24, 2015
  • Article Type: Research Article
  • Received: December 14, 2014
  • Accepted: December 14, 2014
  • DOI: 10.17795/gct-26974

To Cite: Hashemi M, Naderi M, Eskandari Nasab E, Hasani S S, Sadeghi Bojd S, et al. Evaluation of 40-bp Insertion/Deletion Polymorphism of MDM2 and the Risk of Childhood Acute Lymphoblastic Leukemia, Gene Cell Tissue. 2015 ; 2(1):e26974. doi: 10.17795/gct-26974.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Swinney RM, Hsu SC, Hirschman BA, Chen TT, Tomlinson GE. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia. 2005; 19(11): 1996-8[DOI][PubMed]
  • 2. Canalle R, Burim RV, Tone LG, Takahashi CS. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen. 2004; 43(2): 100-9[DOI][PubMed]
  • 3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810): 307-10[DOI][PubMed]
  • 4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3): 323-31[PubMed]
  • 5. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med. 1997; 3(7): 441-51[PubMed]
  • 6. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002; 12(1): 53-9[PubMed]
  • 7. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630): 296-9[DOI][PubMed]
  • 8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630): 299-303[DOI][PubMed]
  • 9. Gao J, Kang AJ, Lin S, Dai ZJ, Zhang SQ, Liu D, et al. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls. Ther Clin Risk Manag. 2014; 10: 269-77[DOI][PubMed]
  • 10. Zhuo X, Ren J, Li D, Wu Y, Zhou Q. MDM2 SNP309 variation increases cervical cancer risk among Asians. Tumour Biol. 2014; 35(6): 5331-7[DOI][PubMed]
  • 11. Wang LH, Wang X, Xu WT, Hu YL. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol. 2014; 35(4): 3167-70[DOI][PubMed]
  • 12. Dong D, Gao X, Zhu Z, Yu Q, Bian S, Gao Y. A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population. Gene. 2012; 497(1): 66-70[DOI][PubMed]
  • 13. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer. 2006; 118(5): 1275-8[DOI][PubMed]
  • 14. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006; 240(2): 261-7[DOI][PubMed]
  • 15. Hashemi M, Omrani M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Taheri M. A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast cancer in Zahedan, Southeast Iran. Iran Biomed J. 2014; 18(4): 245-9[PubMed]
  • 16. Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M, Sheybani-Nasab M. A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumour Biol. 2014; 35(1): 219-25[DOI][PubMed]
  • 17. Hashemi M, Ebrahimi M, Amininia S, Naderi M, Eskandari-Nasab E, Taheri M. Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran. Int J Hematol Oncol Stem Cell Res. 2014; 8(4): 39-44
  • 18. Hashemi M, Sheybani-Nasab M, Naderi M, Roodbari F, Taheri M. Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. Tumour Biol. 2014; 35(10): 10375-9[DOI][PubMed]
  • 19. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, Lepage P, et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics. 2004; 16(2): 184-93[DOI][PubMed]
  • 20. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993; 82(9): 2617-23[PubMed]
  • 21. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358(6381): 80-3[DOI][PubMed]
  • 22. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53(10 Suppl): 2231-4[PubMed]
  • 23. Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma. 2012; 53(11): 2245-52[DOI][PubMed]
  • 24. Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, et al. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. Mol Carcinog. 2014; 53(12): 951-9[DOI][PubMed]
  • 25. Chen J, Zhu B, Chen J, Li Y. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol. 2013; 32(7): 414-9[DOI][PubMed]
  • 26. Zhang X, Gu L, Li J, Shah N, He J, Yang L, et al. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010; 70(23): 9895-904[DOI][PubMed]
  • 27. Wang W, Du M, Gu D, Zhu L, Chu H, Tong N, et al. MDM2 SNP309 polymorphism is associated with colorectal cancer risk. Sci Rep. 2014; 4: 4851[DOI][PubMed]
  • 28. Zhao Y, Yang X, Hao X, Pan X, Zhao B, Ma J, et al. Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies. Tumour Biol. 2014; 35(8): 7555-60[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments